세계의 바이러스성 간염 시장 보고서(2025년)

Viral Hepatitis Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

바이러스성 간염 시장 규모는 향후 몇 년 동안 안정적인 성장세를 보일 것으로 예상되며, 2029년에는 연평균 4.2%의 CAGR로 199억 7,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 치료 접근성, 공중보건법, 병용요법, 건강 형평성에 대한 노력에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 맞춤형 치료 계획, 디지털 건강 도구, 질병 모니터링의 AI, C형 간염의 미세 제거 등이 있습니다.

간염의 유병률 증가는 향후 몇 년 동안 바이러스성 간염 시장의 성장을 촉진할 것으로 예상됩니다. 간염은 다양한 감염성 바이러스 및 비감염성 물질에 의해 유발되는 간 감염을 말하며, 여러 가지 건강 합병증을 유발하며, A형 간염, B형 간염, C형 간염, D형 간염, E형 간염은 간에 염증과 손상을 유발하는 바이러스성 간염의 원인 바이러스 중 일부입니다. 예를 들어, 2024년 4월 스웨덴에 본부를 둔 정부 보건 기관인 유럽질병예방통제센터는 2022년 EU/EEA 30개국에서 28,855건의 B형 간염 바이러스(HBV) 감염 사례를 보고했으며, 이는 2021년에 기록된 16,187건보다 78% 증가한 수치입니다. 또한 2022년 총 환자 수는 28,420명으로 인구 10만 명당 8.5명의 조 환자 수를 기록했습니다. 따라서 간염 유병률의 증가는 바이러스성 간염 시장의 확대를 촉진할 것으로 보입니다.

바이러스성 간염 시장의 강력한 성장 요인으로 연구개발(R&D)의 증가가 예상됩니다. 바이러스성 간염에 초점을 맞춘 R&D 활동은 백신, 항바이러스제, 진단 검사, 역학 조사, 공중 보건 개입, 유전체 연구, 예방 전략, 세계 보건 캠페인, 임상시험, 중복 감염 조사 등의 개발을 포함한 광범위한 활동을 포괄합니다. 연구개발 활동의 활성화는 치료 접근법의 혁신을 촉진할 뿐만 아니라 진단 및 예방의 선택권을 넓혀줍니다. 그 결과, 임상시험의 수가 증가하고, 세계 보건에 대한 노력이 강화되며, 제약 회사 간의 경쟁이 치열해집니다. 예를 들어, 2022년 11월, 멜버른의 연구자들은 mRNA 빅토리아 활성화 프로그램을 통해 향후 5년간 170만 달러의 자금을 확보했습니다. 이 자금은 B형 간염 바이러스 감염 치료법을 찾기 위한 선구적인 연구를 진전시킬 것입니다. 그 결과, 연구개발 활동의 활성화가 바이러스성 간염 시장 성장의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 바이러스성 간염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 이용 산업 분석
• 세계의 바이러스성 간염 시장 : 성장률 분석
• 세계의 바이러스성 간염 시장 실적 : 규모와 성장, 2019-2024
• 세계의 바이러스성 간염 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 바이러스성 간염 전체 시장(TAM)

제6장 시장 세분화

• 세계의 바이러스성 간염 시장 : 질환 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• A형 간염
• B형 간염
• C형 간염
• 기타 질병 종류
• 세계의 바이러스성 간염 시장 : 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 간생검
• 혈액 검사
• 영상 검사
• 기타 진단
• 세계의 바이러스성 간염 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 항바이러스제
• 수술
• 백신
• 면역조절제
• 기타 치료법
• 세계의 바이러스성 간염 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 비경구
• 기타 투여 경로
• 세계의 바이러스성 간염 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 전문 클리닉
• 홈케어
• 기타 최종사용자
• 세계의 바이러스성 간염 시장, A형 간염 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 급성 A형 간염
• 만성 A형 간염
• 세계의 바이러스성 간염 시장, B형 간염 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 급성 B형 간염
• 만성 B형 간염
• B형 간염 캐리어
• 세계의 바이러스성 간염 시장 C형 간염 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 급성 C형 간염
• 만성 C형 간염
• 세계의 바이러스성 간염 시장, 기타 질환 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• D형 간염
• E형 간염

제7장 지역별·국가별 분석

• 세계의 바이러스성 간염 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 바이러스성 간염 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 바이러스성 간염 시장 : 경쟁 구도
• 바이러스성 간염 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb
• Astra Zeneca Pharmaceuticals LP
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Co. Ltd.
• Hetero Drugs Ltd.
• Eisai Co. Ltd.
• Boehringer Ingelheim Group
• Sun Pharmaceutical Industries Ltd.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 바이러스성 간염 시장 2029 : 새로운 기회를 제공하는 국가
• 바이러스성 간염 시장 2029 : 새로운 기회를 제공하는 부문
• 바이러스성 간염 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Viral hepatitis encompasses a group of infectious diseases resulting from various viruses (hepatitis A, B, C, D, and E), primarily affecting the liver. The symptoms may vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting, and fever.

The primary types of viral hepatitis diseases include hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a potentially life-threatening liver ailment caused by the hepatitis A virus. Diagnosis is typically achieved through liver biopsy, blood tests, imaging tests, and other diagnostic methods. Treatment options involve antiviral drugs, surgery, vaccines, immune modulator drugs, and others. These treatments can be administered through various routes, including oral and parenteral, and are commonly offered in hospitals, specialty clinics, homecare settings, and other relevant healthcare facilities.

The viral hepatitis market research report is one of a series of new reports from The Business Research Company that provides viral hepatitis market statistics, including viral hepatitis industry global market size, regional shares, competitors with a viral hepatitis market share, detailed viral hepatitis market segments, market trends and opportunities and any further data you may need to thrive in the viral hepatitis industry. This viral hepatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral hepatitis market size has grown steadily in recent years. It will grow from $16.21 billion in 2024 to $16.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.97 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.

The increasing prevalence of hepatitis is expected to drive the growth of the viral hepatitis market in the coming years. Hepatitis refers to a liver infection caused by various infectious viruses and non-infectious substances, leading to several health complications. Hepatitis A, B, C, D, and E are some of the viruses responsible for viral hepatitis, which causes liver inflammation and damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a government health agency based in Sweden, reported 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from the 16,187 cases recorded in 2021. Furthermore, the total number of cases in 2022, which amounted to 28,420, represented a crude rate of 8.5 cases per 100,000 people. Therefore, the growing prevalence of hepatitis will fuel the expansion of the viral hepatitis market.

The increasing volume of research and development (R&D) endeavors is expected to serve as a powerful growth driver for the viral hepatitis market. Research and development initiatives focused on viral hepatitis encompass a wide spectrum of activities, including the development of vaccines, antiviral medications, diagnostic tests, epidemiological studies, public health interventions, genomic research, prevention strategies, global health campaigns, clinical trials, and investigations into co-infections. The upsurge in R&D activities not only fosters innovation in treatment approaches but also expands the array of options for diagnosis and prevention. This, in turn, leads to a higher number of clinical trials, stronger global health initiatives, and heightened competition among pharmaceutical companies. For instance, in November 2022, researchers in Melbourne secured funding of $1.7 million for the next five years through the mRNA Victoria Activation Program. This funding is set to advance their pioneering work in the quest for a cure for hepatitis B virus infection. Consequently, the escalation in the number of research and development activities is a driving force behind the growth of the viral hepatitis market.

Prominent companies active in the viral hepatitis market are dedicated to advancing the development of new drugs to reinforce their position within the market. The pursuit of drug development and innovation serves to enrich scientific understanding by shedding light on disease mechanisms, thus expediting the creation of novel treatments. For instance, in November 2022, Gilead Sciences Inc., a biopharmaceutical company based in the United States, disclosed the FDA's granting of the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. These tablets are designed for once-daily administration to address chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. The approval for Vemlidy's utilization in this specific group of pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.

In November 2023, GSK plc, a pharmaceuticals company based in the U.K., acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With the acquisition of the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to enhance its portfolio and reinforce its position in the chronic hepatitis B treatment space by adding a new and potentially valuable therapy. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, is known for developing treatments for infectious diseases, including chronic hepatitis B.

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the viral hepatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Hepatitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral hepatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral hepatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral hepatitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
• 2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
• 3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A
• 2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier
• 3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C
• 4) By Other Disease Types: Hepatitis D; Hepatitis E
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Co; F Hoffmann-La Roche AG; Merck & Co.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Viral Hepatitis Market Characteristics

3. Viral Hepatitis Market Trends And Strategies

4. Viral Hepatitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Viral Hepatitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Viral Hepatitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Viral Hepatitis Market Growth Rate Analysis
• 5.4. Global Viral Hepatitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Viral Hepatitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Viral Hepatitis Total Addressable Market (TAM)

6. Viral Hepatitis Market Segmentation

• 6.1. Global Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Other Disease Types
• 6.2. Global Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liver Biopsy
• Blood Tests
• Imaging Tests
• Other Diagnosis
• 6.3. Global Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Drugs
• Surgery
• Vaccine
• Immune Modulator Drugs
• Other Treatments
• 6.4. Global Viral Hepatitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.5. Global Viral Hepatitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis A
• Chronic Hepatitis A
• 6.7. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis B
• Chronic Hepatitis B
• Hepatitis B Carrier
• 6.8. Global Viral Hepatitis Market, Sub-Segmentation Of Hepatitis C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Hepatitis C
• Chronic Hepatitis C
• 6.9. Global Viral Hepatitis Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis D
• Hepatitis E

7. Viral Hepatitis Market Regional And Country Analysis

• 7.1. Global Viral Hepatitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Viral Hepatitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral Hepatitis Market

• 8.1. Asia-Pacific Viral Hepatitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral Hepatitis Market

• 9.1. China Viral Hepatitis Market Overview
• 9.2. China Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral Hepatitis Market

• 10.1. India Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral Hepatitis Market

• 11.1. Japan Viral Hepatitis Market Overview
• 11.2. Japan Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral Hepatitis Market

• 12.1. Australia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral Hepatitis Market

• 13.1. Indonesia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral Hepatitis Market

• 14.1. South Korea Viral Hepatitis Market Overview
• 14.2. South Korea Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral Hepatitis Market

• 15.1. Western Europe Viral Hepatitis Market Overview
• 15.2. Western Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral Hepatitis Market

• 16.1. UK Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral Hepatitis Market

• 17.1. Germany Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral Hepatitis Market

• 18.1. France Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral Hepatitis Market

• 19.1. Italy Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral Hepatitis Market

• 20.1. Spain Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral Hepatitis Market

• 21.1. Eastern Europe Viral Hepatitis Market Overview
• 21.2. Eastern Europe Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral Hepatitis Market

• 22.1. Russia Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral Hepatitis Market

• 23.1. North America Viral Hepatitis Market Overview
• 23.2. North America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral Hepatitis Market

• 24.1. USA Viral Hepatitis Market Overview
• 24.2. USA Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral Hepatitis Market

• 25.1. Canada Viral Hepatitis Market Overview
• 25.2. Canada Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral Hepatitis Market

• 26.1. South America Viral Hepatitis Market Overview
• 26.2. South America Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral Hepatitis Market

• 27.1. Brazil Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral Hepatitis Market

• 28.1. Middle East Viral Hepatitis Market Overview
• 28.2. Middle East Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral Hepatitis Market

• 29.1. Africa Viral Hepatitis Market Overview
• 29.2. Africa Viral Hepatitis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Viral Hepatitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Viral Hepatitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral Hepatitis Market Competitive Landscape And Company Profiles

• 30.1. Viral Hepatitis Market Competitive Landscape
• 30.2. Viral Hepatitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Viral Hepatitis Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi SA
• 31.3. Bristol-Myers Squibb
• 31.4. Astra Zeneca Pharmaceuticals LP
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Gilead Sciences Inc.
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Astellas Pharma Inc.
• 31.11. Daiichi Sankyo Co. Ltd.
• 31.12. Hetero Drugs Ltd.
• 31.13. Eisai Co. Ltd.
• 31.14. Boehringer Ingelheim Group
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Viral Hepatitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral Hepatitis Market

34. Recent Developments In The Viral Hepatitis Market

35. Viral Hepatitis Market High Potential Countries, Segments and Strategies

• 35.1 Viral Hepatitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Viral Hepatitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Viral Hepatitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료